C4 Therapeutics, Inc. financial data

Symbol
CCCC on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
490 Arsenal Way, Suite 120, Watertown, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Feb 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 550 % -15.7%
Debt-to-equity 56.1 % +3.03%
Return On Equity -43.7 % +21%
Return On Assets -28 % +21.8%
Operating Margin -336 % +49.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 71M shares +3.17%
Common Stock, Shares, Outstanding 70.6M shares +16.8%
Entity Public Float 306M USD +136%
Common Stock, Value, Issued 7K USD +16.7%
Weighted Average Number of Shares Outstanding, Basic 69.4M shares +39.8%
Weighted Average Number of Shares Outstanding, Diluted 69.4M shares +39.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 35.6M USD +71.4%
Research and Development Expense 111M USD -6.01%
General and Administrative Expense 42.1M USD +0.1%
Operating Income (Loss) -120M USD +14%
Nonoperating Income (Expense) 14.4M USD +84.6%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -105M USD +19.8%
Income Tax Expense (Benefit) 131K USD -89.8%
Net Income (Loss) Attributable to Parent -105M USD +20.5%
Earnings Per Share, Basic -1.52 USD/shares +43.1%
Earnings Per Share, Diluted -1.52 USD/shares +43.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 55.5M USD -56.2%
Cash, Cash Equivalents, and Short-term Investments 267M USD -5.11%
Accounts Receivable, after Allowance for Credit Loss, Current 3.1M USD -73.7%
Assets, Current 258M USD -4.95%
Property, Plant and Equipment, Net 5.84M USD -18.1%
Operating Lease, Right-of-Use Asset 57.5M USD -10%
Other Assets, Noncurrent 2.66M USD -2.5%
Assets 350M USD -7.13%
Accounts Payable, Current 1.33M USD -8.16%
Contract with Customer, Liability, Current 18.7M USD +20.9%
Liabilities, Current 45.2M USD +5.64%
Contract with Customer, Liability, Noncurrent 28.5M USD +30.5%
Operating Lease, Liability, Noncurrent 60M USD -8.78%
Liabilities 134M USD +2.52%
Accumulated Other Comprehensive Income (Loss), Net of Tax 53K USD
Retained Earnings (Accumulated Deficit) -634M USD -19.9%
Stockholders' Equity Attributable to Parent 216M USD -12.2%
Liabilities and Equity 350M USD -7.13%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -18.1M USD +45.3%
Net Cash Provided by (Used in) Financing Activities 34.6M USD
Net Cash Provided by (Used in) Investing Activities -53.4M USD -200%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 70.6M shares +16.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -36.9M USD -287%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 58.9M USD -54.7%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 174M USD +19.2%
Deferred Tax Assets, Gross 192M USD +15.6%
Operating Lease, Liability 65.8M USD -7.36%
Depreciation 1.47M USD -6.65%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -105M USD +18.2%
Lessee, Operating Lease, Liability, to be Paid 80.2M USD -9.92%
Property, Plant and Equipment, Gross 15.1M USD +1.23%
Operating Lease, Liability, Current 5.77M USD +10.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 9.37M USD +3%
Lessee, Operating Lease, Liability, to be Paid, Year One 9.09M USD +3%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 14.5M USD -20%
Lessee, Operating Lease, Liability, to be Paid, Year Three 9.65M USD +2.99%
Deferred Tax Assets, Operating Loss Carryforwards 62.4M USD +2.28%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 11.4M USD +17.8%
Operating Lease, Payments 2.18M USD +3.02%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 29.7M USD +8.91%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%